Toxic dense-dose therapy for ovarian cancer not justified












Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

The current chemotherapy treatment regime for ovarian cancer is single dose every three weeks. In 2013 a Japanese clinical trial* showed increased survival with a dose-dense regime where a double dose of the same chemotherapy is administered weekly.

There is a significant increase in side effects and toxicity with this dose-dense regime. A repeat randomised clinical trial has been completed comparing dose-dense therapy with conventional less toxic treatment regimes.

The findings of this large study with 1566 participants shows no improvement of progression free survival with the dose-dense therapy. Most side effects from treatment were greater with the dose-dense regime. The incidence of nerve injury and decreased white blood cell count was similar for all groups.


Comments

Popular posts from this blog

An impossible dream?

It’s not just your genotype

Sugar doesn’t feed cancer